About Agile Therapeutics (NASDAQ:AGRX)
Agile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AGRX
CUSIPN/A
Phone609-683-1880
Debt
Debt-to-Equity RatioN/A
Current Ratio2.57%
Quick Ratio2.57%
Price-To-Earnings
Trailing P/E Ratio-3.00
Forward P/E Ratio-3.85
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.06 per share
Price / Book2.58
Profitability
EPS (Most Recent Fiscal Year)($0.91)
Net Income$-28,300,000.00
Net MarginsN/A
Return on Equity-79.38%
Return on Assets-53.19%
Miscellaneous
Employees21
Outstanding Shares34,250,000
Agile Therapeutics (NASDAQ:AGRX) Frequently Asked Questions
What is Agile Therapeutics' stock symbol?
Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."
How were Agile Therapeutics' earnings last quarter?
Agile Therapeutics (NASDAQ:AGRX) issued its quarterly earnings data on Monday, March, 12th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. View Agile Therapeutics' Earnings History.
What price target have analysts set for AGRX?
6 Wall Street analysts have issued twelve-month price targets for Agile Therapeutics' stock. Their forecasts range from $5.00 to $13.00. On average, they expect Agile Therapeutics' share price to reach $9.00 in the next twelve months. View Analyst Ratings for Agile Therapeutics.
What are Wall Street analysts saying about Agile Therapeutics stock?
Here are some recent quotes from research analysts about Agile Therapeutics stock:
- 1. HC Wainwright analysts commented, "it as Just Another Delay; Reiterate Buy but Lower to $8 Stock Data 12/21/2017 Price $4.76 Exchange NASDAQ Price Target $8.00 52-Week High $6.62 52-Week Low $2.04 Enterprise Value (M) $131.3 Market Cap (M) $163 Shares Outstanding (M) 34.2 3 Month Avg Volume 267,948 Short Interest (M) 0.30 Balance Sheet Metrics Cash (M) $43.8 Total Debt (M) $12.1 Total Cash/Share $1.28 EPS Diluted Full Year – Dec 2016A 2017E 2018E 1Q (0.27) (0.26)A (0.28) 2Q (0.29) (0.26)A (0.26) 3Q (0.27) (0.22)A (0.29) 4Q (0.18) (0.24) (0.32) FY (1.02) (0.98) (1.16) Revenue ($M) Full Year – Dec 2016A 2017E 2018E 1Q 0.0 0.0A 0.0 2Q 0.0 0.0A 0.0 3Q 0.0 0.0A 0.0 4Q 0.0 0.0 0.0 FY 0.0 0.0 0.0 7 6 5 4 3 2 1 DEC- 16 APR- 17 AUG- 17 DEC- 17 20 15 10 5 0 Vol. (mil) Price Twirla Complete Response Letter surprisingly focused on patch adhesion; we believe the issues are readily addressable. The consensus investor Twirla sticking issue has been around the “high” Phase 3 Pearl Index (implied lower efficacy) vs. prior." (12/22/2017)
- 2. Cantor Fitzgerald analysts commented, "One time when you’re happy to receive a belated Christmas present. The PDUFA date for Twirla is December 26, and we believe it reasonable that an approval will occur around then. We suppose it might be possible that FDA staffers clear their plates before the holiday season. AGRX management has deftly avoided addressing whether labeling discussions have occurred as that would be an indication that FDA approval could be forthcoming." (11/6/2017)
Who are some of Agile Therapeutics' key competitors?
Some companies that are related to Agile Therapeutics include Xoma (XOMA), Summit Therapeutics (SMMT), Nabriva Therapeutics (NBRV), Zafgen (ZFGN), Teligent (TLGT), Protagonist Therapeutics (PTGX), Spero Therapeutics (SPRO), Kamada (KMDA), Immune Design (IMDZ), Spring Bank Pharmaceuticals (SBPH), Proteostasis Therapeutics (PTI), Avid Bioservices (CDMO), Intec Pharma (NTEC), XBiotech (XBIT), NewLink Genetics (NLNK), Newron Pharmaceuticals (NWPHF), Tetraphase Pharmaceuticals (TTPH) and Acer Therapeutics (ACER).
Who are Agile Therapeutics' key executives?
Agile Therapeutics' management team includes the folowing people:
- Mr. Alfred F. Altomari, Chairman, Chief Exec. Officer and Pres (Age 59)
- Mr. Scott M. Coiante, CFO & Sr. VP (Age 51)
- Dr. Elizabeth Ijeoma Onyemelukwe Garner M.D., M.P.H., Chief Medical Officer and Sr. VP (Age 50)
- Ms. Mary Coleman, Head of Investor Relations & Corp. Communications
- Mr. Geoffrey P. Gilmore, Gen. Counsel (Age 52)
Has Agile Therapeutics been receiving favorable news coverage?
News headlines about AGRX stock have been trending somewhat negative recently, Accern Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Agile Therapeutics earned a media sentiment score of -0.01 on Accern's scale. They also gave headlines about the specialty pharmaceutical company an impact score of 47.80 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.
How do I buy shares of Agile Therapeutics?
Shares of AGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Agile Therapeutics' stock price today?
One share of AGRX stock can currently be purchased for approximately $2.73.
How big of a company is Agile Therapeutics?
Agile Therapeutics has a market capitalization of $97.95 million. The specialty pharmaceutical company earns $-28,300,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Agile Therapeutics employs 21 workers across the globe.
How can I contact Agile Therapeutics?
Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The specialty pharmaceutical company can be reached via phone at 609-683-1880 or via email at [email protected]
MarketBeat Community Rating for Agile Therapeutics (AGRX)
MarketBeat's community ratings are surveys of what our community members think about Agile Therapeutics and other stocks. Vote "Outperform" if you believe AGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Agile Therapeutics (NASDAQ:AGRX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Agile Therapeutics in the last 12 months. Their average twelve-month price target is $9.00, suggesting that the stock has a possible upside of 229.67%. The high price target for AGRX is $13.00 and the low price target for AGRX is $5.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.67 | 2.71 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $9.00 | $9.00 | $9.20 | $10.20 |
| Price Target Upside: | 229.67% upside | 182.13% upside | 233.33% upside | 98.83% upside |
Agile Therapeutics (NASDAQ:AGRX) Consensus Price Target History
Agile Therapeutics (NASDAQ:AGRX) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Agile Therapeutics (NASDAQ:AGRX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Agile Therapeutics (NASDAQ AGRX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 71.03%
Agile Therapeutics (NASDAQ AGRX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/25/2017 | Alfred Altomari | Chairman | Buy | 10,000 | $3.34 | $33,400.00 | 161,587 |  |
| 8/25/2017 | Renee Selman | Insider | Buy | 7,250 | $3.35 | $24,287.50 | 60,583 | |
| 5/11/2017 | Alfred Altomari | Chairman | Buy | 10,000 | $3.51 | $35,100.00 | 151,587 | |
| 5/11/2017 | Renee Selman | Insider | Buy | 53,333 | $3.68 | $196,265.44 | 53,333 | |
| 1/27/2016 | Jay Moorin | Major Shareholder | Buy | 393,700 | $6.35 | $2,499,995.00 | | |
| 6/2/2015 | Alfred Altomari | CEO | Buy | 2,500 | $8.73 | $21,825.00 | | |
| 1/23/2015 | Jay Moorin | Major Shareholder | Buy | 811,966 | $5.85 | $4,750,001.10 | | |
| 5/29/2014 | Care Capital Iii Llc | Major Shareholder | Buy | 500,000 | $6.00 | $3,000,000.00 | | |
| 5/23/2014 | Andrew N Schiff | Director | Buy | 1,333,333 | $6.00 | $7,999,998.00 | | |
| 5/22/2014 | Ab Investor | Major Shareholder | Buy | 1,000,000 | $6.00 | $6,000,000.00 | | |
(Data available from 1/1/2013 forward)
Agile Therapeutics (NASDAQ AGRX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Agile Therapeutics (AGRX) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - April 19 at 5:45 AM |
| Agile Therapeutics (AGRX) Earns Buy Rating from Analysts at HC Wainwright
www.americanbankingnews.com - April 17 at 12:04 AM |
| Agile Therapeutics (AGRX) Expected to Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - April 16 at 1:10 PM |
| Noble Financial Reaffirms "Buy" Rating for Agile Therapeutics (AGRX)
www.americanbankingnews.com - April 15 at 9:45 AM |
| HC Wainwright Reaffirms Buy Rating for Agile Therapeutics (AGRX)
www.americanbankingnews.com - April 8 at 3:15 PM |
| Cantor Fitzgerald Comments on Agile Therapeutics' FY2019 Earnings (AGRX)
www.americanbankingnews.com - April 6 at 8:23 AM |
| Agile Therapeutics (AGRX) Expected to Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - March 30 at 3:10 PM |
 | What Should Investors Know About Agile Therapeutics Inc’s (NASDAQ:AGRX) Long Term Outlook?
finance.yahoo.com - March 28 at 5:19 PM |
 | Pre-Market Technical Scan on Generic Drugs Equities -- Adamas Pharma, Agile Therapeutics, Catalent, and Diplomat Pharmacy
www.prnewswire.com - March 26 at 8:22 AM |
| Agile Therapeutics (AGRX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 25 at 5:32 AM |
| New Research: Key Drivers of Growth for At Home Group, Griffon, Mitek, J & J Snack Foods, Lindsay, and Agile Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
finance.yahoo.com - March 23 at 8:18 AM |
| Is Agile Therapeutics Inc’s (NASDAQ:AGRX) Balance Sheet A Threat To Its Future?
finance.yahoo.com - March 20 at 5:18 PM |
| Agile Therapeutics (AGRX) Receives "Buy" Rating from Noble Financial
www.americanbankingnews.com - March 15 at 6:44 PM |
| Agile Therapeutics Inc (AGRX) Forecasted to Earn Q1 2018 Earnings of ($0.19) Per Share
www.americanbankingnews.com - March 15 at 7:36 AM |
 | Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition - GlobeNewswire (press release)
globenewswire.com - March 14 at 8:31 AM |
| Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition
finance.yahoo.com - March 14 at 8:31 AM |
| -$0.28 EPS Expected for Agile Therapeutics Inc (AGRX) This Quarter
www.americanbankingnews.com - March 13 at 1:57 PM |
| HC Wainwright Reaffirms "Buy" Rating for Agile Therapeutics (AGRX)
www.americanbankingnews.com - March 13 at 1:38 PM |
 | Agile Therapeutics Reports Fourth Quarter and Full Year 2017 ... - Nasdaq
www.nasdaq.com - March 13 at 8:25 AM |
| Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 13 at 8:25 AM |
| Agile Therapeutics Inc (AGRX) Sees Significant Decline in Short Interest
www.americanbankingnews.com - March 13 at 1:08 AM |
| Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 12 at 6:40 PM |
| Agile Therapeutics Inc (AGRX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - February 28 at 5:36 AM |
| Agile Therapeutics Inc (AGRX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 3 at 5:28 AM |
| New Research Coverage Highlights Oracle, General Dynamics, Agile Therapeutics, Fidelity Southern, Syros Pharmaceuticals, and MSA Safety Incorporated — Consolidated Revenues, Company Growth, and Expectations for 2018
finance.yahoo.com - January 24 at 8:06 AM |
| Technical Perspectives on Generic Drugs Stocks -- Fibrocell Science, Galectin Therapeutics, Agile Therapeutics, and ... - PR Newswire (press release)
www.prnewswire.com - January 20 at 7:25 AM |
| Agile Therapeutics Inc (AGRX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 9 at 7:58 AM |
| Zacks: Brokerages Anticipate Agile Therapeutics Inc (AGRX) to Announce -$0.24 EPS
www.americanbankingnews.com - January 4 at 7:28 PM |
| Agile Therapeutics (AGRX) Rating Reiterated by Noble Financial
www.americanbankingnews.com - December 29 at 5:04 PM |
| Agile Therapeutics (AGRX) Stock Rating Lowered by Janney Montgomery Scott
www.americanbankingnews.com - December 29 at 5:04 PM |
| HC Wainwright Analysts Give Agile Therapeutics (AGRX) a $8.00 Price Target
www.americanbankingnews.com - December 29 at 3:34 PM |
| FY2017 EPS Estimates for Agile Therapeutics Inc (AGRX) Decreased by Cantor Fitzgerald
www.americanbankingnews.com - December 29 at 7:56 AM |
 | Agile Therapeutics: Sell-Off Post CRL Makes It Worth A Look - Seeking Alpha
seekingalpha.com - December 27 at 9:58 AM |
| Critical Contrast: Relypsa (RLYP) and Agile Therapeutics (AGRX)
www.americanbankingnews.com - December 26 at 8:01 PM |
| Agile Therapeutics (AGRX) Downgraded to Market Perform at William Blair
www.americanbankingnews.com - December 26 at 7:36 AM |
| Agile Therapeutics' (AGRX) "Buy" Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - December 25 at 1:32 PM |
| Agile Therapeutics (AGRX) Stock Rating Reaffirmed by Noble Financial
www.americanbankingnews.com - December 25 at 12:38 PM |
 | Agile Therapeutics plunges toward record low after FDA rejects contraceptive patch's NDA - MarketWatch
www.marketwatch.com - December 23 at 3:46 PM |
| Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® (AG200-15) for the Prevention ... - GlobeNewswire (press release)
globenewswire.com - December 23 at 3:46 PM |
 | Agile Therapeutics (AGRX) Receives CRL from FDA for Twirla for Prevention of Pregnancy
www.streetinsider.com - December 22 at 8:42 PM |
| Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® (AG200-15) for the Prevention of Pregnancy
finance.yahoo.com - December 22 at 8:42 PM |
| Agile Therapeutics plunges toward record low after FDA rejects contraceptive patch's NDA
finance.yahoo.com - December 22 at 8:42 PM |
| Agile Therapeutics (AGRX) PT Set at $8.00 by HC Wainwright
www.americanbankingnews.com - December 22 at 3:58 PM |
| Mid-Day Market Update: Ignyta Surges Following Merger Deal With Roche; Agile Therapeutics Shares Plunge - Nasdaq
www.nasdaq.com - December 22 at 3:40 PM |
| Agile Therapeutics (AGRX) Receives CRL from FDA for Twirla for Prevention of Pregnancy - StreetInsider.com
www.streetinsider.com - December 22 at 3:40 PM |
| Who Are The Largest Shareholders In Agile Therapeutics Inc (NASDAQ:AGRX)?
finance.yahoo.com - December 21 at 3:24 PM |
| Agile Therapeutics, Inc. (AGRX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - December 15 at 5:52 AM |
| Head to Head Survey: Agile Therapeutics (AGRX) vs. Celsion (CLSN)
www.americanbankingnews.com - December 13 at 5:12 AM |
| Is It Too Late To Buy Agile Therapeutics Inc (AGRX)?
finance.yahoo.com - December 1 at 3:24 PM |
| Agile Therapeutics, Inc. (AGRX) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - November 20 at 6:46 PM |
Agile Therapeutics (NASDAQ:AGRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Agile Therapeutics (NASDAQ:AGRX) Income Statement, Balance Sheet and Cash Flow Statement
Agile Therapeutics (NASDAQ AGRX) Stock Chart for Friday, April, 20, 2018
Loading chart…
